Practical Norms and Academic Innovations in the Development Process of Thoracic Surgery_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

冯思阳 ,  蔡开灿

南方医科大学南方医院胸心血管外科（广州 510515）;

Corresponding author：

蔡开灿, Email: doc_cai@163.com

Keywords：

胸外科; 诊疗规范; 创新

DOI：

10.7507/1007-4848.20150202

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 冯思阳, 蔡开灿. Practical Norms and Academic Innovations in the Development Process of Thoracic Surgery. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2015, 22(9): 803-806. doi: 10.7507/1007-4848.20150202 Copy

1.	石应康. 胸部创伤外科的历史回顾与展望. 中国胸心血管外科临床杂志, 2014, 21(3):399-401.
2.	Graham EA, Singer JJ. Successful removal of an entire lung for carcinoma of the bronchus. CA Cancer J Clin, 1974, 24(4):238-242.
3.	Okada M, Yoshikawa K, Hatta T, et al. Is segmentectomy with lymph node assessment an alternative to lobectomy for non-small cell lung cancer of 2 cm or smaller? Ann Thorac Surg, 2001, 71(3):956-961.
4.	Koike T, Yamato Y, Yoshiya K, et al. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J Thorac Cardiovasc Surg, 2003, 125(4):924-928.
5.	Martin-Ucar AE, Nakas A, Pilling JE, et al. A case-matched study of anatomical segmentectomy versus lobectomy for stage I lung cancer in high-risk patients. Eur J Cardiothorac Surg, 2005, 27(4):675-679.
6.	Nakamura H, Kawasaki N, Taguchi M, et al. Survival following lobectomy vs limited resection for stage I lung cancer:a metaanalysis. Br J Cancer, 2005, 92(6):1033-1037.
7.	Okada M, Koike T, Higashiyama M, et al. Radical sublobar resection for small-sized non-small cell lung cancer:a multicenter study. J Thorac Cardiovasc Surg, 2006, 132(4):769-775.
8.	支修益,石远凯,于金明. 中国原发性肺癌诊疗规范(2015年版).中华肿瘤杂志, 2015, 37(1):67-78.
9.	刘伦旭,车国卫,蒲强,等. 单向式全胸腔镜肺叶切除术. 中华胸心血管外科杂志, 2008, 24(3):156-158.
10.	Cai K, Wu H, Ren P, et al. Unidirectionally progressive resection of lower right lung cancer under video-assisted thoracoscopy. J Thorac Dis, 2013, 5(Suppl 3):S310-S314.
11.	Cai K, Ren P, Feng S, et al. Unidirectionally progressive left pneumonectomy & mediastinal lymph node dissection. J Thorac Dis, 2013, 5(6):886-891.
12.	Cai K, Feng S, Wu H, et al. Unidirectionally thoracoscopic resection of lingual segment of the left upper pulmonary lobe. J Thorac Dis, 2014, 6(9):1358-1363.
13.	Cai K, Zhao H, Wu H, et al. Unidirectionally progressive resection of left upper pulmonary lobe under video-assisted thoracoscopy. J Thorac Dis,2014,6(12):1843-1847.
14.	Gonzalez D, Paradela M, Garcia J, et al. Single-port video-assisted thoracoscopiclobectomy. Interact Cardiovasc Thorac Surg, 2011, 12(3):514-515.
15.	Wang BY, Liu CY, Hsu PK, et al. Single-incision versus multipleincision thoracoscopic lobectomy and segmentectomy:a propensity-matched analysis. Ann Surg, 2015, 261(4):793-799.
16.	Paul S, Jalbert J, Isaacs AJ, et al. Comparative effectiveness of robotic-assisted vs thoracoscopic lobectomy. Chest, 2014, 146(6):1505.
17.	Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10):947-957.
18.	Han JY, Park K, Kim SW, et al. First-SIGNAL:first-line singleagent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol, 2012, 30(10):1122-1128.
19.	Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25):2380-2388.
20.	Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405):an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2):121-128.
21.	Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer(OPTIMAL, CTONG-0802):a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8):735-742.
22.	Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC):a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13(3):239-246.
23.	Sequist LV, Yang JCH, Yamamoto N, et al. Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013, 31(27):3327-3334.
24.	Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced nonsmall-cell lung cancer harbouring EGFR mutations(LUX-Lung 6):an open-label, randomised phase 3 trial. Lancet Oncol, 2014, 15(2):213-222.
25.	National CCN. The NCCN clinical practice guidelines in oncology(NCCN guidelines) for non-small cell lung cancer. Version 2.2015[Z].
26.	石应康,张尔永,刘雪梅. 关于我国胸心外科住院医师规范化培训制度的讨论. 中国胸心血管外科临床杂志, 2015, 22(3):181-183.

1. 石应康. 胸部创伤外科的历史回顾与展望. 中国胸心血管外科临床杂志, 2014, 21(3):399-401.
2. Graham EA, Singer JJ. Successful removal of an entire lung for carcinoma of the bronchus. CA Cancer J Clin, 1974, 24(4):238-242.
3. Okada M, Yoshikawa K, Hatta T, et al. Is segmentectomy with lymph node assessment an alternative to lobectomy for non-small cell lung cancer of 2 cm or smaller? Ann Thorac Surg, 2001, 71(3):956-961.
4. Koike T, Yamato Y, Yoshiya K, et al. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J Thorac Cardiovasc Surg, 2003, 125(4):924-928.
5. Martin-Ucar AE, Nakas A, Pilling JE, et al. A case-matched study of anatomical segmentectomy versus lobectomy for stage I lung cancer in high-risk patients. Eur J Cardiothorac Surg, 2005, 27(4):675-679.
6. Nakamura H, Kawasaki N, Taguchi M, et al. Survival following lobectomy vs limited resection for stage I lung cancer:a metaanalysis. Br J Cancer, 2005, 92(6):1033-1037.
7. Okada M, Koike T, Higashiyama M, et al. Radical sublobar resection for small-sized non-small cell lung cancer:a multicenter study. J Thorac Cardiovasc Surg, 2006, 132(4):769-775.
8. 支修益,石远凯,于金明. 中国原发性肺癌诊疗规范(2015年版).中华肿瘤杂志, 2015, 37(1):67-78.
9. 刘伦旭,车国卫,蒲强,等. 单向式全胸腔镜肺叶切除术. 中华胸心血管外科杂志, 2008, 24(3):156-158.
10. Cai K, Wu H, Ren P, et al. Unidirectionally progressive resection of lower right lung cancer under video-assisted thoracoscopy. J Thorac Dis, 2013, 5(Suppl 3):S310-S314.
11. Cai K, Ren P, Feng S, et al. Unidirectionally progressive left pneumonectomy & mediastinal lymph node dissection. J Thorac Dis, 2013, 5(6):886-891.
12. Cai K, Feng S, Wu H, et al. Unidirectionally thoracoscopic resection of lingual segment of the left upper pulmonary lobe. J Thorac Dis, 2014, 6(9):1358-1363.
13. Cai K, Zhao H, Wu H, et al. Unidirectionally progressive resection of left upper pulmonary lobe under video-assisted thoracoscopy. J Thorac Dis,2014,6(12):1843-1847.
14. Gonzalez D, Paradela M, Garcia J, et al. Single-port video-assisted thoracoscopiclobectomy. Interact Cardiovasc Thorac Surg, 2011, 12(3):514-515.
15. Wang BY, Liu CY, Hsu PK, et al. Single-incision versus multipleincision thoracoscopic lobectomy and segmentectomy:a propensity-matched analysis. Ann Surg, 2015, 261(4):793-799.
16. Paul S, Jalbert J, Isaacs AJ, et al. Comparative effectiveness of robotic-assisted vs thoracoscopic lobectomy. Chest, 2014, 146(6):1505.
17. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10):947-957.
18. Han JY, Park K, Kim SW, et al. First-SIGNAL:first-line singleagent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol, 2012, 30(10):1122-1128.
19. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25):2380-2388.
20. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405):an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2):121-128.
21. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer(OPTIMAL, CTONG-0802):a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8):735-742.
22. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC):a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13(3):239-246.
23. Sequist LV, Yang JCH, Yamamoto N, et al. Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013, 31(27):3327-3334.
24. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced nonsmall-cell lung cancer harbouring EGFR mutations(LUX-Lung 6):an open-label, randomised phase 3 trial. Lancet Oncol, 2014, 15(2):213-222.
25. National CCN. The NCCN clinical practice guidelines in oncology(NCCN guidelines) for non-small cell lung cancer. Version 2.2015[Z].
26. 石应康,张尔永,刘雪梅. 关于我国胸心外科住院医师规范化培训制度的讨论. 中国胸心血管外科临床杂志, 2015, 22(3):181-183.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Practical Norms and Academic Innovations in the Development Process of Thoracic Surgery

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content